• About us
• Contact

Advertisement

Organisation › Details

Selexis S.A.

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 95 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. *

 

	Start	2001-01-01 established
	Group	JSR Corporation (Group)
	Industry	SUREtechnology Platform™ (Selexis)
	Industry 2	CHO cell line
	Person	Fisch, Igor (NewBiologix 202305 CEO + Co-Founder before Selexis CEO + co-founder)
	Person 2	Onakunle, Yemi (JSR Corp 202001– promoted to CBO of Selexis joined 2012 before Diosynth RTP Inc + Lonza)
	Region	Plan-les-Ouates GE
	Country	Switzerland
	Street	18 Chemin des Aulx
	City	1228 Plan-les-Ouates GE
	Tel	+41-22-308-9360
		Address record changed: 2024-01-05
Basic data	Employees	B: 11 to 50 (2017-05-11)
		* Document for »About Section«: Selexis S.A.. (2/26/18). "Press Release: Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates". Geneva.
		Record changed: 2023-07-10

Advertisement

More documents for JSR Corporation (Group)

• [1] Crown Bioscience, Inc.. (4/4/23). "Press Release: Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank". San Diego, CA....
• [2] Indivumed GmbH. (1/25/23). "Press Release: Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank". San Diego, CA & Hamburg....
• [3] Selexis S.A.. (5/2/22). "Press Release: JSR Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA". Sunnyvale, CA....
• [4] Selexis S.A.. (3/18/21). "Press Release: SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program". Geneva....
• [5] Selexis S.A.. (10/20/20). "Press Release: JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland". Sunnyvale, CA....
• [6] Selexis S.A.. (10/16/20). "Press Release: Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer". Geneva....
• [7] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
• [8] Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva....
• [9] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
• [10] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.